What antimicrobial regimen should be used to treat a carbapenem‑resistant Klebsiella pneumoniae infection and a concurrent Enterococcus faecalis infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Carbapenem-Resistant Klebsiella pneumoniae with Concurrent Enterococcus faecalis

For dual infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) and Enterococcus faecalis, use combination therapy targeting both organisms: ceftazidime-avibactam (if KPC-producing) or polymyxin-based combination for CRKP, plus ampicillin for E. faecalis coverage. 1, 2

Algorithmic Approach to Treatment Selection

Step 1: Determine CRKP Carbapenemase Type

The carbapenemase profile fundamentally determines optimal therapy:

For KPC-producing CRKP (most common in many regions):

  • First-line: Ceftazidime-avibactam is the preferred agent for serine carbapenemase producers 1
  • If ceftazidime-avibactam resistant: Add a β-lactam to ceftazidime-avibactam (synergy rates 79.7-86.5%) 3
  • Alternative: Polymyxin + ceftazidime-avibactam combination (53.2% synergy rate even in polymyxin-resistant isolates) 3

For NDM-producing CRKP (metallo-β-lactamase):

  • Ceftazidime-avibactam + aztreonam (83.3% synergistic activity) 3
  • This combination works because aztreonam is stable against MBLs while avibactam protects aztreonam from other β-lactamases

For KPC+NDM co-producers:

  • Ceftazidime-avibactam + aztreonam showed synergistic or additive effects in 100% of isolates despite individual agent resistance 3

Step 2: Add Enterococcal Coverage

Since E. faecalis is present concurrently, you must add specific enterococcal coverage:

  • Ampicillin is the agent of choice for E. faecalis (assuming susceptibility) 2
  • This is critical because E. faecalis is intrinsically resistant to cephalosporins and has variable susceptibility to other agents
  • If using a regimen that doesn't cover enterococcus (e.g., ceftriaxone-metronidazole for intra-abdominal infections), ampicillin must be added 2

Step 3: Consider Polymyxin-Based Combinations if Newer Agents Unavailable

If ceftazidime-avibactam is not available or the isolate is resistant:

Polymyxin combination therapy is strongly recommended over monotherapy for CRKP infections 1:

  • Reduces mortality by 14 fewer deaths per 1000 patients (RR 0.97)
  • Reduces treatment failure by 119 fewer failures per 1000 patients (RR 0.82)
  • Reduces pathogen eradication failure by 74 fewer failures per 1000 patients (RR 0.81)

Specific polymyxin combinations:

  • Polymyxin + carbapenem (meropenem): Use only if meropenem MIC ≤8 mg/L for CRE, with high-dose extended-infusion meropenem (3-hour infusion) 1
  • Polymyxin + fosfomycin: If isolate susceptible to fosfomycin (39-99% susceptibility rates in CRKP) 1
  • Polymyxin + tigecycline: Demonstrated synergistic activity 1

Critical caveat: Monotherapy with colistin-polymyxin B or tigecycline had 66.7% mortality despite in vitro susceptibility, compared to 13.3% with combination therapy 4. This underscores that combination therapy is essential for bacteremia and serious CRKP infections.

Step 4: Optimize Dosing and Monitoring

Therapeutic drug monitoring (TDM) should be performed for 1:

  • Polymyxins (narrow therapeutic index)
  • Aminoglycosides (if used)
  • Carbapenems (especially high-dose extended-infusion regimens)

Monitor renal function closely during polymyxin treatment and avoid combining with other nephrotoxic or ototoxic agents 1.

Practical Regimen Examples

Scenario 1: KPC-producing CRKP + E. faecalis (ceftazidime-avibactam available)

  • Ceftazidime-avibactam 2.5g IV q8h
  • PLUS Ampicillin 2g IV q4-6h (for E. faecalis)

Scenario 2: NDM-producing CRKP + E. faecalis

  • Ceftazidime-avibactam 2.5g IV q8h + Aztreonam 2g IV q8h
  • PLUS Ampicillin 2g IV q4-6h

Scenario 3: CRKP + E. faecalis (newer agents unavailable)

  • Colistin (loading dose 9 million units, then 4.5 million units q12h) + Meropenem 2g IV over 3 hours q8h (if MIC ≤8 mg/L)
  • PLUS Ampicillin 2g IV q4-6h
  • Consider adding fosfomycin if susceptible

Scenario 4: Respiratory tract infection with CRKP + E. faecalis

  • Add aerosolized polymyxin to intravenous polymyxin (may reduce mortality by 50 deaths per 1000 patients, RR 0.86) 1
  • Continue systemic therapy as above

Critical Pitfalls to Avoid

  1. Do not use monotherapy for CRKP bacteremia or serious infections - mortality approaches 58-67% with monotherapy versus 12-13% with combination therapy 4

  2. Do not forget enterococcal coverage - E. faecalis is intrinsically resistant to cephalosporins and ceftazidime-avibactam; ampicillin must be added 2, 5

  3. Do not combine polymyxin with other nephrotoxic agents without careful monitoring 1

  4. Do not use polymyxin-carbapenem combinations if meropenem MIC >8 mg/L - unlikely to be effective 1

  5. Avoid fosfomycin in patients with hypernatremia or cardiac/renal insufficiency 1

  6. Do not assume in vitro synergy translates to clinical benefit - one study showed colistin-meropenem in vitro synergism did not improve outcomes in severe CRGNB infections 1

Special Considerations

For polymicrobial infections where carbapenem cannot be used (e.g., E. faecium which is intrinsically carbapenem-resistant), consider sulbactam-durlobactam + tigecycline as demonstrated in a recent case report 5. However, this applies to E. faecium, not E. faecalis.

Obtain antimicrobial susceptibility testing and consider synergy testing (checkerboard method, time-killing curves) to guide combination selection, particularly in treatment failures 1.

Related Questions

Can Unasyn (Ampicillin/Sulbactam) be switched to oral therapy in a patient with Klebsiella pneumoniae (KPN) bacteremia who is sensitive to Unasyn, or is intravenous therapy necessary for the full treatment course?
What is the appropriate dosing regimen of cefoperazone‑sulbactam combined with tigecycline for a patient with abdominal‑origin sepsis caused by extensively drug‑resistant Acinetobacter baumannii?
What is the best course of treatment for an elderly patient with a UTI due to Klebsiella pneumoniae, acute delirium, and multiple comorbidities, including chronic respiratory failure, anemia, and traumatic skin tears?
For a patient with Acinetobacter baumannii infection on tigecycline who now has severe thrombocytopenia, should tigecycline be stopped and a polymyxin B plus sulbactam regimen started?
What is the recommended approach for antibiotic synergy testing in patients with Klebsiella infections?
What is the recommended dosing regimen and duration for acyclovir suppressive therapy in patients with frequent recurrent genital herpes, including adjustments for renal impairment?
What are the side effects of immunoglobulin therapy (intravenous immunoglobulin [IVIG] or subcutaneous immunoglobulin [SCIG])?
What is the next step in managing a 67‑year‑old chronic dialysis patient on amitriptyline who became psychotic and combative, received 250 mg intramuscular ketamine, is now asleep with a normal head CT, normal routine labs except markedly elevated serum creatinine, and is at a hospital without dialysis capability?
Can you provide a SOAP note with appropriate CPT and ICD‑10 codes for a 44‑year‑old female elementary school teacher presenting with possible acute conjunctivitis (pink eye), a history of hypertension and depression, no known drug allergies, and red eyes with drainage and crusting?
What amount and sources of soluble dietary fiber are recommended to lower LDL cholesterol?
In a 47-year-old perimenopausal woman, should vaginal estradiol be used to prevent urinary tract infections?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.